430 related articles for article (PubMed ID: 20446853)
1. Pemetrexed in advanced non-small-cell lung cancer.
Fuld AD; Dragnev KH; Rigas JR
Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
[TBL] [Abstract][Full Text] [Related]
4. The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.
Gridelli C; Di Maio M
Expert Opin Pharmacother; 2010 Feb; 11(2):321-4. PubMed ID: 20053140
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
Bearz A; Garassino I; Cavina R; Favaretto A; Boccalon M; Talamini R; Berretta M; Spazzapan S; Simonelli C; Santoro A; Tirelli U
Lung Cancer; 2008 May; 60(2):240-5. PubMed ID: 18022729
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed for the treatment of non-small-cell lung cancer.
Manegold C; Schmid-Bindert G; Pilz LR
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed in advanced non-small cell lung cancer.
Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
[TBL] [Abstract][Full Text] [Related]
8. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E; Casillas M; Cassinello A
Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
[TBL] [Abstract][Full Text] [Related]
11. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
13. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Scagliotti GV; Selvaggi G
Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
15. [Update of pemetrexed in thoracic oncology].
Brechot JM; Morère JF
Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
[TBL] [Abstract][Full Text] [Related]
16. Review of a promising new agent--pemetrexed disodium.
Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
18. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
[TBL] [Abstract][Full Text] [Related]
19. [Second-line treatment of advanced non-small-cell lung cancer: role of pemetrexed].
Pérol M
Rev Pneumol Clin; 2005 Sep; 61(4 Pt 2):4S14-7. PubMed ID: 16273004
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.
Ohe Y; Ichinose Y; Nakagawa K; Tamura T; Kubota K; Yamamoto N; Adachi S; Nambu Y; Fujimoto T; Nishiwaki Y; Saijo N; Fukuoka M
Clin Cancer Res; 2008 Jul; 14(13):4206-12. PubMed ID: 18594001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
